Journals / Eastern Journal of Medicine / 2021 / Cilt: 26 - Sayı: 3

Abnormal First and Second Trimester Maternal Serum Marker Levels For Aneuploidy Screening and Adverse Pregnancy Outcomes

Pages
418–425
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant relationship could be established between low 1st trimester free hCG levels (less than 0.5MoMs) and any of the adverse outcomes.First and 2nd trimester serum analytes for Down syndrome screening are significantly linked with pregnancy complications.However, because their sensitivity and positive predictive values are low, these analytes are not shown to be effective inthe screening of pregnancy complications when used alone.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To investigate if there is an association between pregnancy complications and abnormal maternal serum analytes used forfirst trimester screening (FTS) and second trimester screening (STS) for aneuploidy.More than two hundred three pregnant women who had FTS or STS for Down's syndrome who presented between July2009 and January 2010 were included.
📊
Key Findings & Data:First trimester maternal levels of PAPP-A and free hCG or 2nd trimester maternallevels of AFP, uE3 and hCG were compared between healthy pregnancies and those with preeclampsia, intrauterinegrowth retardation, intrauterine fetal death or oligohydramnios.PAPP-A levels less than 0.4 MoMs were related with elevated preeclampsia and fetal growth retardation risk.
💡
Conclusion & Impact:No significant relationship could be established between low 1st trimester free hCG levels (less than 0.5MoMs) and any of the adverse outcomes.First and 2nd trimester serum analytes for Down syndrome screening are significantly linked with pregnancy complications.However, because their sensitivity and positive predictive values are low, these analytes are not shown to be effective inthe screening of pregnancy complications when used alone.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Özet

To investigate if there is an association between pregnancy complications and abnormal maternal serum analytes used forfirst trimester screening (FTS) and second trimester screening (STS) for aneuploidy.More than two hundred three pregnant women who had FTS or STS for Down's syndrome who presented between July2009 and January 2010 were included. First trimester maternal levels of PAPP-A and free hCG or 2nd trimester maternallevels of AFP, uE3 and hCG were compared between healthy pregnancies and those with preeclampsia, intrauterinegrowth retardation, intrauterine fetal death or oligohydramnios.PAPP-A levels less than 0.4 MoMs were related with elevated preeclampsia and fetal growth retardation risk. AFP levelsover 2.5 MoMs were related with all adverse outcomes evaluated in the study including preeclampsia, fetal growthretardation, intrauterine fetal demise and oligohydramnios. While uE3 levels below 0.5 MoM were found to be related withhigher preeclampsia incidence, elevated 2nd trimester hCG levels over 3.0 MoMs were associated with fetal growthretardation. No significant relationship could be established between low 1st trimester free hCG levels (less than 0.5MoMs) and any of the adverse outcomes.First and 2nd trimester serum analytes for Down syndrome screening are significantly linked with pregnancy complications.However, because their sensitivity and positive predictive values are low, these analytes are not shown to be effective inthe screening of pregnancy complications when used alone.

🔖

Cite This Article

KARAKIŞ, L. S., TURKGELDİ, E., KIYAK, H., YÜCEL, N. (2021). Abnormal First and Second Trimester Maternal Serum Marker Levels For Aneuploidy Screening and Adverse Pregnancy Outcomes. Eastern Journal of Medicine, Cilt: 26 - Sayı: 3, 418–425. https://ajindex.com/articles/348297

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Walker JJ. Pre-eclampsia. Lancet. 2000; 356: 1260-1265
  2. Gaccioli F, Aye ILMH, Sovio U, CharnockJones DS, Smith GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol 2018; 218: S725-S737
  3. Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Norgaard-Pedersen B, et al. Second-trimester maternal serum alphafetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 2001; 97: 277-282
  4. Gagnon A, Wilson RD, Audibert F, et al Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30: 918-949
  5. Dugoff L. Society for Maternal-Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010; 115: 1052-1061
  6. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. Firsttrimester maternal serum PAPP-A and freebeta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial). Am J Obstet Gynecol 2004; 191: 1446-1451
  7. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol 2020; 135: 1492-1495
  8. Yaron Y, Cherry M, Kramer RL, et al. Secondtrimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999; 181: 968-967
  9. Dugoff L, Cuckle HS, Hobbins JC, et al. FaSTER Trial Research Consortium. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. Am J Obstet Gynecol. 2008; 199: 290
  10. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008; 28: 7-10
  11. Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme firsttrimester free human chorionic gonadotropinbeta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191: 1452-1458
  12. Huang T, Hoffman B, Mesch